Kura Oncology (KURA) Tops Q2 EPS by 11c, Beats on Revenue

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. ANT
3. SPY
4. FFAI
5. FFR
6. CART
7. LLY
8. TSLA
9. META
10. FICO

Go back to Kura Oncology (KURA) Tops Q2 EPS by 11c, Beats on Revenue

Kura Oncology Reports Second Quarter 2026 Financial Results

August 12, 2026 4:02 PM EDT

KOMZIFTI® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q

KOMZIFTI® achieved majority share of new patient starts in R/R NPM1-m AML menin inhibitor class, establishing leadership after just two full quarters of launch

Long-term, frontline AML data presented at EHA 2026 support potential for ziftomenib to transform standard of care and a $7 billion TAM

Clinical updates support darlifarnibs potential to enhance targeted therapies in RCC and KRAS-mutated tumors

$519.0 million in cash,... More